Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T16:46:11.576Z Has data issue: false hasContentIssue false

Section 9 - Management of Peripheral Neuropathies

Published online by Cambridge University Press:  20 April 2018

Mark B. Bromberg
Affiliation:
University of Utah
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Peripheral Neuropathies
A Practical Approach
, pp. 193 - 204
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Carter, GT. Rehabilitation management of peripheral neuropathy. Semin Neurol. 2005;25:229–37.CrossRefGoogle ScholarPubMed
Geboers, JF, Janssen-Potten, YJ, Seelen, HA, Spaans, F, Drost, MR. Evaluation of effect of ankle-foot orthosis use on strength restoration of paretic dorsiflexors. Arch Phys Med Rehabil. 2001;82:856–60.CrossRefGoogle ScholarPubMed
Schaper, NC, Van Netten, JJ, Apelqvist, J, Lipsky, BA, Bakker, K. Prevention and management of foot problems in diabetes: a Summary Guidance for Daily Practice 2015, based on the IWGDF Guidance Documents. Diabetes Metab Res Rev. 2016;32 Suppl 1:715.CrossRefGoogle ScholarPubMed
Singleton, JR, Smith, AG, Marcus, RL. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep. 2015;15:120.CrossRefGoogle ScholarPubMed
Vinci, P, Gargiulo, P. Poor compliance with ankle-foot-orthoses in Charcot-Marie-Tooth disease. Eur J Phys Rehabil Med. 2008;44:2731.Google ScholarPubMed

References

Adrichem, ME, Eftimov, F, van Schaik, IN. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. J Peripher Nerv Syst. 2016;21:121–7.CrossRefGoogle Scholar
Aitkens, S, Lord, J, Bernauer, E, Fowler, WM, Jr., Lieberman, JS, Berck, P. Relationship of manual muscle testing to objective strength measurements. Muscle Nerve. 1989;12:173–7.CrossRefGoogle ScholarPubMed
Allen, JA, Lewis, RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85:498504.CrossRefGoogle ScholarPubMed
Anderson, CR, Olson, JA. Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels. Am J Health Syst Pharm. 2015;72:285–9.CrossRefGoogle ScholarPubMed
Baron, R, Binder, A, Wasner, G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807–19.CrossRefGoogle ScholarPubMed
Berger, M, Allen, JA. Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve. 2015;51:315–26.CrossRefGoogle ScholarPubMed
Bril, V, England, J, Franklin, GM, Backonja, M, Cohen, J, Del Toro, D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–65.CrossRefGoogle Scholar
Bromberg, MB, Carter, O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve. 2004;30:2037.CrossRefGoogle ScholarPubMed
Brouwer, BA, de Greef, BT, Hoeijmakers, JG, Geerts, M, van Kleef, M, Merkies, IS, et al. Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects. Drugs Aging. 2015;32:611–21.CrossRefGoogle ScholarPubMed
Chin, RL, Deng, C, Bril, V, Hartung, HP, Merkies, IS, Donofrio, PD, et al. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse. Muscle Nerve. 2015.CrossRefGoogle ScholarPubMed
Draak, TH, Gorson, KC, Vanhoutte, EK, van Nes, SI, van Doorn, PA, Cornblath, DR, et al. Correlation of the patient’s reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies. European journal of neurology. 2016;23:1248–53.CrossRefGoogle ScholarPubMed
Finnerup, NB, Attal, N, Haroutounian, S, McNicol, E, Baron, R, Dworkin, RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–73.CrossRefGoogle ScholarPubMed
Gilron, I, Baron, R, Jensen, T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90:532–45.CrossRefGoogle ScholarPubMed
Hanewinckel, R, Ikram, MA, van Doorn, PA. Assessment scales for the diagnosis of polyneuropathy. J Peripher Nerv Syst. 2016;21:6173.CrossRefGoogle ScholarPubMed
Hughes, R, Bensa, S, Willison, H, Van den Bergh, P, Comi, G, Illa, I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195201.CrossRefGoogle ScholarPubMed
Hughes, RA, Donofrio, P, Bril, V, Dalakas, MC, Deng, C, Hanna, K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.CrossRefGoogle Scholar
Hughes, RA, Mehndiratta, MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;1:CD002062.Google ScholarPubMed
Kaplan, A, Brannagan, TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2017; 55:476–82.CrossRefGoogle ScholarPubMed
Latov, N, Deng, C, Dalakas, MC, Bril, V, Donofrio, P, Hanna, K, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67:802–7.CrossRefGoogle ScholarPubMed
Lunn, MP, Ellis, L, Hadden, RD, Rajabally, YA, Winer, JB, Reilly, MM. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21:33–7.CrossRefGoogle ScholarPubMed
Mehndiratta, MM, Huges, RA, Prichard, J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrand Database System Rev. 2015;CD003906.Google ScholarPubMed
Racosta, JM, Sposato, LA, Kimpinski, K. Subcutaneous vs. Intravenous Immunoglobulin for Chronic Autoimmune Neuropathies: A Meta-analysis. Muscle Nerve. 2017;55:802–9.CrossRefGoogle Scholar
Rajabally, YA. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. J Neurol Neurosurg Psychiatry. 2014;85:631–7.CrossRefGoogle ScholarPubMed
Rajabally, YA, Wong, SL, Kearney, DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol. 2013;260:2052–6.CrossRefGoogle ScholarPubMed
Singleton, JR, Smith, AG, Marcus, RL. Exercise as Therapy for Diabetic and Prediabetic Neuropathy. Curr Diab Rep. 2015;15:120.CrossRefGoogle ScholarPubMed
Uncini, A, Kuwabara, S. Electrodiagnostic criteria for Guillain-Barre syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123:1487–95.CrossRefGoogle ScholarPubMed
van Nes, SI, Faber, CG, Merkies, IS. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials. J Peripher Nerv Syst. 2008;13:136–47.CrossRefGoogle ScholarPubMed
van Nes, SI, Vanhoutte, EK, van Doorn, PA, Hermans, M, Bakkers, M, Kuitwaard, K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337–45.CrossRefGoogle ScholarPubMed
Vanhoutte, EK, Faber, CG, van Nes, SI, Cats, EA, Van der Pol, WL, Gorson, KC, et al. Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS((c))). J Peripher Nerv Syst. 2015;20:296305.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×